one search. all jobs. Indeed
 
 
 

Dynavax Technologies

About Dynavax Technologies

Dynavax Technologies Corporation is a biopharmaceutical company that discovers and develops a pipeline of Toll-like Receptor (TLR) product candidates. The Company's product candidates include HEPLISAV, a hepatitis B vaccine; SD-101, a Phase Ib hepatitis C therapy; DV-601, a Phase Ib hepatitis B therapy; Universal Flu vaccine, a preclinical vaccine under – more... a supply and option agreement with Novartis; AZD1419, a preclinical asthma therapy partnered with AstraZeneca AB, and DV1079, a preclinical autoimmune and inflammatory disease therapy partnered with GlaxoSmithKline.
(Source: 10-K) – less – More from ZoomInfo »

Dynavax Technologies Employer Reviews

Be the first to review this employer

Working at Dynavax Technologies

    Headquarters Berkeley California, United States
    Stock Symbol NASDAQ: DVAX
    Industry
    Revenue $40.3 Million
    Employees 51 to 200
    Links